Veenat 400 Mg (Imatinib)

✅ Key Benefits

• High-strength dose ideal for resistant or aggressive disease

• Precisely targets key cancer-driving kinases

• Clinically proven to deepen responses in robust cases

• Convenient once-daily oral dosing improves patient adherence

• Flexible dosing range allows personalized treatment plans

🎯 How to Use

• Administer one 400 mg tablet daily, with or without food

• Swallow whole with water—do not crush, split, or chew

• Continue treatment until disease progression or side effects warrant change

• Monitor regularly: CBC, liver, renal, and cardiac function

• Dose modifications or temporary pauses may be required based on tolerance or lab results

⚠️ Precautions

• Prescription-only medication, to be used under oncologist guidance

• Monitor for fluid retention, hepatotoxicity, myelosuppression

• Cardiac evaluation recommended due to rare risk of heart failure

• Use effective contraception during treatment and several months afterward

• Check for drug interactions, especially with CYP3A4 substrates or inhibitors

🤕 Possible Side Effects

• Common: Edema, nausea, diarrhea, muscle cramps, fatigue

• Hematologic: Neutropenia, anemia, thrombocytopenia

• Hepatic: Elevated liver enzymes; rare jaundice

• Cardiac: In rare cases, heart failure or reduced function

• Other: Skin rash, headache, fever

❓ Frequently Asked Questions (FAQs)

Q. Who is Veenat 400 mg intended for?
A. Patients with resistant or advanced CML, Ph+ ALL, or c‑KIT positive GIST requiring higher drug exposure for effective disease control.

Q. Can it be taken with food?
A. Yes—consistent timing with or without food is recommended for steady absorption.

Q. What monitoring is essential?
A. Regular blood counts, liver and kidney function tests, and cardiac screening are necessary to ensure safety and efficacy.

Q. How long is treatment continued?
A. Usually prolonged while patients derive benefit and tolerate therapy; stopping depends on remission status or toxicity concerns.